SCHEMBL4041957

SCHEMBL4041957

O=C(NC(Cc1cccs1)C(=O)N1CCC2C1C(=O)CN2C(=O)Cc1cccnc1)c1ccc(-c2cccs2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.42
HPGDS O60760 1/20 0.41
HDAC1 Q13547 4/20 0.40
ACE P12821 2/20 0.38
DRD2 P14416 3/20 0.36
DRD4 P21917 3/20 0.36
HTR2A P28223 1/20 0.36
MC4R P32245 1/20 0.36
MC5R P33032 1/20 0.36
MC3R P41968 1/20 0.36
DPP4 P27487 1/20 0.36
PREP P48147 1/20 0.36
CHRNA7 P36544 2/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
CHRM4 P08173 1/20 0.36
CTSL P07711 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040781 0.92 CTSK (0.42) CTSKHPGDSHDAC1ACEDRD2
SCHEMBL4040750 0.92 CTSK (0.52) CTSKHPGDSHDAC1CHRNA7CHRNB2
SCHEMBL4047289 0.91 CTSK (0.43) CTSKHPGDSHDAC1ACEDRD2
SCHEMBL4044071 0.90 CTSK (0.54) CTSKACEMC4RMC5RMC3R
SCHEMBL4042863 0.89 CTSK (0.44) CTSKACEMC4RMC5RMC3R
SCHEMBL4041209 0.87 HPGDS (0.39) CTSKHPGDSHDAC1ACEDRD2
SCHEMBL4040456 0.85 CTSK (0.39) CTSKHPGDSDRD2DRD4MC4R
SCHEMBL4041118 0.84 CTSK (0.39) CTSKHPGDSHDAC1ACEDRD2
SCHEMBL4046253 0.83 CTSK (0.60) CTSKHPGDSDRD2DRD4HTR2A
SCHEMBL4043220 0.82 CTSK (0.48) CTSKHPGDSDRD2DRD4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
EP-1463728-B1 FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL MYERS SQUIBB CO (US) 2009-01-14 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885HPGDS 603/4885HDAC1 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.